

2019 Wet (Neovascular/Exudative) Macular Degeneration Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

<https://marketpublishers.com/r/22EAF454822EN.html>

Date: February 2019

Pages: 146

Price: US\$ 2,199.00 (Single User License)

ID: 22EAF454822EN

Abstracts

The ongoing clinical trial research report- “2019 Wet (Neovascular / Exudative) Macular Degeneration Ongoing Clinical Trials Study” analyzes the current scenario of all active Wet (Neovascular / Exudative) Macular Degeneration trials across the world. The report presents top level analysis of global Wet (Neovascular / Exudative) Macular Degeneration clinical trials across countries, companies and universities. It is designed to provide clear understanding into the Wet (Neovascular / Exudative) Macular Degeneration trials landscape to assist users for effective long term strategy formulation to beat competition.

The report covers a key snapshot of ongoing trial count, average enrollment per trial across countries.

It also segments the Wet (Neovascular / Exudative) Macular Degeneration clinical trials by-

Region (Asia Pacific, Europe, Middle East Africa and Americas)

Countries

Trial Phase

Current Trial Status (Recruiting, Active, Planned, Active but Completed Recruiting, Not Yet Recruiting etc)

Type of the trial (Interventional, Observational)

Sponsor Type (Companies, Universities, Government Bodies etc)

Enrollment across types, sponsor types, geographies, current status and phases

The report also identifies the potential drug candidates under development for treatment of Wet (Neovascular / Exudative) Macular Degeneration on the basis of intervention type ongoing Wet (Neovascular / Exudative) Macular Degeneration trials.

The research work is prepared through extensive and continuous research on Wet (Neovascular / Exudative) Macular Degeneration trials from over 150 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

REPORT SCOPE AND COVERAGE:

All major ongoing trials from 2010 to 2019 and planned trials are included in the report scope.

Drug candidates currently being researched for administering Wet (Neovascular / Exudative) Macular Degeneration patients are identified

The report includes panorama of ongoing Wet (Neovascular / Exudative) Macular Degeneration clinical trials across the globe

Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided

Companies and universities focusing on Wet (Neovascular / Exudative) Macular Degeneration clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)

Average Enrollment number, insights into enrollment trends, company wise enrollment are included

Both interventional and observational studies are analyzed

News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Wet (Neovascular / Exudative) Macular Degeneration Ongoing Clinical Trials Overview, 2019

2.2 Premium Insights into Ongoing Clinical Trials

2.2.1 Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Region

2.2.2 Average Enrollment of Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials

2.2.3 Companies participating in Ongoing Trials

2.2.4 Drugs under Study for Wet (Neovascular / Exudative) Macular Degeneration Treatment, 2019

3. REGION WISE WET (NEOVASCULAR / EXUDATIVE) MACULAR DEGENERATION CLINICAL TRIALS

3.1 Asia Pacific Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Country

3.2 Europe Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Country

3.3 North America Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Country

3.4 Middle East and Africa Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Country

3.5 South and Central America Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Country

4. WET (NEOVASCULAR / EXUDATIVE) MACULAR DEGENERATION CLINICAL TRIAL TRENDS

4.1 Start Year wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials

4.2 Phase wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials

4.3 Trial Status wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials

4.4 Trial Type wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials

5. WET (NEOVASCULAR / EXUDATIVE) MACULAR DEGENERATION AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Wet (Neovascular / Exudative) Macular Degeneration Trials by Year

5.2 Average Enrollment in Wet (Neovascular / Exudative) Macular Degeneration Trials by Phase

5.3 Average Enrollment in Wet (Neovascular / Exudative) Macular Degeneration Trials by Status

5.4 Average Enrollment in Wet (Neovascular / Exudative) Macular Degeneration Trials by Type of Trial

6. COMPANIES PARTICIPATING IN ONGOING WET (NEOVASCULAR / EXUDATIVE) MACULAR DEGENERATION CLINICAL TRIALS

6.1 Ongoing Wet (Neovascular / Exudative) Macular Degeneration Trials by Sponsor Type

6.2 Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Sponsor Type

6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Ongoing Wet (Neovascular / Exudative) Macular Degeneration Trials- Phase

7.2 Ongoing Wet (Neovascular / Exudative) Macular Degeneration Trials- Phase

7.3 Ongoing Wet (Neovascular / Exudative) Macular Degeneration Trials- Phase

7.4 Ongoing Wet (Neovascular / Exudative) Macular Degeneration Trials- Phase

8. APPENDIX

- 8.1 Report Guidance
- 8.2 Research Methodology
- 8.3 Abbreviations
- 8.4 Definitions
- 8.5 Sources
- 8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

- Figure 1: Wet (Neovascular / Exudative) Macular Degeneration Ongoing Clinical Trials by Region, 2019
- Figure 2: Country wise Clinical Trials, 2019
- Figure 3: Country wise Average Enrolment, 2019
- Figure 4: Asia Pacific – Country wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
- Figure 5: Europe – Country wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
- Figure 6: Middle East Africa – Country wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
- Figure 7: North America – Country wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
- Figure 8: South and Central America – Country wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
- Figure 9: Wet (Neovascular / Exudative) Macular Degeneration Ongoing Clinical Trials by Phase
- Figure 10: Wet (Neovascular / Exudative) Macular Degeneration Ongoing Clinical Trials by Trial Status
- Figure 11: Wet (Neovascular / Exudative) Macular Degeneration Ongoing Clinical Trials by Type
- Figure 12: Wet (Neovascular / Exudative) Macular Degeneration Ongoing Clinical Trials by Sponsor Type
- Figure 13: Wet (Neovascular / Exudative) Macular Degeneration Ongoing Clinical Trials by Leading Sponsors
- Figure 14: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Phase
- Figure 15: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Trial Status
- Figure 16: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Type
- Figure 17: Wet (Neovascular / Exudative) Macular Degeneration- Average Enrolment by Type of Sponsors
- Figure 18: Wet (Neovascular / Exudative) Macular Degeneration- Enrolment by Leading Sponsors
- Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Wet (Neovascular / Exudative) Macular Degeneration Ongoing Clinical Trials Snapshot- 2019

Table 2: Ongoing Trials by Region, 2019

Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019

Table 4: Asia Pacific – Country wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment

Table 5: Europe – Country wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment

Table 6: Middle East Africa – Country wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment

Table 7: North America – Country wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment

Table 8: South and Central America – Country wise Ongoing Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment

Table 9: Clinical Trials by Phase

Table 10: Clinical Trials by Trial Status

Table 11: Clinical Trials by Type

Table 12: Clinical Trials by Sponsor Type

Table 13: Clinical Trials by Leading Sponsors

Table 14: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Phase

Table 15: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Trial Status

Table 16: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Type

Table 17: Wet (Neovascular / Exudative) Macular Degeneration- Average Enrolment by Type of Sponsors

Table 18: Wet (Neovascular / Exudative) Macular Degeneration- Enrolment by Leading Sponsors

I would like to order

Product name: 2019 Wet (Neovascular/Exudative) Macular Degeneration Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

Product link: <https://marketpublishers.com/r/22EAF454822EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/22EAF454822EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

